<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>
    <!-- Font Awesome -->
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.9.0/css/all.min.css"
        integrity="sha512-q3eWabyZPc1XTCmF+8/LuE1ozpg5xxn7iO89yfSOd5/oKvyqLngoNGsx8jq92Y8eXJ/IRxQbEC+FGSYxtk2oiw=="
        crossorigin="anonymous" referrerpolicy="no-referrer" />
    <!-- Bootstrap CSS -->
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <!-- Custom CSS -->
    <link rel="stylesheet" href="css/style.css">
</head>

<body>

    <div class="main_page5 position-relative fixedHeight">
        <div class="nav_orange">
            <div class="nav_orange_left">
                <h4 class="GothamBook mb-0">MM1: Ixazomib (NINLARO) is the first and only <br> PI regimen with the convenience of an all-oral <br> administration<sup>1</sup></h4>
            </div>
            <div class="nav_orange_right">
                <img src="img/logo_orange.png" alt="">
            </div>
        </div>
        <!-- page 5 middle box -->
            <div class="page5_middle_box page21_middle_box page28_middle_box mt-3 mb-4">
                <div class="page21_middle_left page34_middle_left">
                    <div>
                        <h4 class="txt_orange GothamBook pt-2 mb-3" style="border-top: 1px solid #ef7622; margin-top: 85px;">TOURMALINE-MM1 CLINICAL TRIAL</h4>
                        <h5 class="page21_blue mb-4 bold">Ixazomib (NINLARO) + Rd 28-day dosing schedule<sup>1</sup></h5>
                        <img class="w-100" src="img/page34_chart.png" alt="" style="max-height: 310px;">
                    </div>
                </div>
            </div>
            <div class="page21_middle_right page34_middle_right mt-5">
                <div class="page21_blue_box mb-5 fs-11">
                    <p class="mb-0 pe-4 GothamLight"><strong>Ixazomib (NINLARO) + Rd requires no <br> additional planned hospital visits</strong> over Rd <br> alone<sup>1</sup></p>
                </div>
                <div class="page21_blue_box">
                    <p class="mb-0 pe-0 GothamLight fs-11">Ixazomib (NINLARO) should be taken at approximately the same time on days 1, 8, and 15 of each treatment cycle at least 1 hour before or at least 2 hours after food. The capsule should be swallowed whole with water. It should not be crushed, chewed, or opened.</p>
                </div>
            </div>
    </div>
        <!--  -->

            <div class="page5_middle_box page5_p_sm w-75 mb-3">
                <p class="GothamLight">*Recommended starting dose of dexamethasone is 40 mg. Treatment with Ixazomib (NINLARO) + Rd for longer than 24 cycles should be based on an individual benefit/risk assessment.<sup>1</sup> MM = multiple myeloma; Rd = REVLIMIDÂ® (lenalidomide) + dexamethasone; PI = proteasome inhibitor</p>
            </div>


            <div class="footer_page5">
                <div class="d-flex align-items-end">
                    <div class="page5_btns_md">
                        <a href="../page5/index.html"><p class="mb-0 position-relative">MM1 study design</p></a>
                        <a href="../page6/index.html"><p class="mb-0 position-relative">MM1 patient baseline characteristics</p></a>
                        <a href="../page8/index.html"><p class="mb-0 position-relative">RWE study Hajek et al.</p></a>
                        <a href="../page15/index.html"><p class="mb-0 position-relative">RWE study Terpos et al.</p></a>
                        <a href="../page11/index.html"><p class="mb-0 position-relative">RWE study Chari et al.</p></a>
                        <a href="../page18/index.html"><p class="mb-0 position-relative">RWE study Minarik et al.</p></a>
                        <a href="../page21/index.html"><p class="mb-0 position-relative">MM1 PFS</p></a>
                        <a href="../page23/index.html"><p class="mb-0 position-relative">MM1 PFS in patients with high-risk cytogenetics</p></a>
                        <a href="../page25/index.html"><p class="mb-0 position-relative">MM1 response rate</p></a>
                        <a href="../page28/index.html"><p class="mb-0 position-relative">MM1 PFS in <br> pre-treated patients</p></a>
                        <a href="../page31/index.html"><p class="mb-0 position-relative">MM1 safety data</p></a>
                        <a href="../page34/index.html"><p class="mb-0 position-relative">Dosing</p></a>
                        <a href="../page36/index.html"><p class="mb-0 position-relative">Summary</p></a>
                        <a href="../page38/index.html"><p class="mb-0 position-relative">MM6 data</p></a>
                        <a></a>
                    </div>
                    <div class="footer_inner_nav1 position-static ms-auto bg-transparent p-0">
                        <ul>
                            <li>
                                <a href="../page4/index.html"><img src="img/page_1_footer_icon_1.svg" alt=""></a>
                            </li>
                            <li>
                                <a href="https://onetakeda.app.box.com/s/reg7tviee8telgupc6cccshjet2wqqqh" target="_blank" class="text-uppercase">pi</a>
                            </li>
                            <li>
                                <a href="../page35/index.html" class="text-uppercase">ref</a>
                            </li>
                        </ul>
                    </div>
                </div>
            </div>
    </div>

</body>

</html>